are the oral 17-alpha-alkylated anabolic steroids liver-safe?
oral survival through first-pass metabolism is part of the pharmacology and part of the hepatic-risk problem.
verdict: liver-safe claim contradicted (label warnings and controlled human harm signals)
quick answer
no. Oxandrolone, methandienone, stanozolol, and oxymetholone are 17-alpha-alkylated oral androgens. Labels and controlled human studies document liver-enzyme elevations, cholestatic and neoplastic warnings, and dose-linked toxicity.
the evidence
the risk appears in primary human records. (supported)
Oxandrolone's burn trial recorded more marked ALT elevations than placebo. Oxymetholone trials recorded dose-linked liver-enzyme toxicity. Stanozolol produced major adverse lipid changes in a controlled crossover.
one compound's reputation does not erase its label. (gap)
Words such as mild, dry, or less androgenic are not liver-safety endpoints. Historical approval also does not mean current marketing or low risk.
combining oral records does not create a validated stack. (risk)
No controlled human trial establishes the safety of concurrent 17-alpha-alkylated oral compounds. Class overlap raises concern without supplying a protocol.
bottom line
different molecules and formulations have different records, but none earns a liver-safe label.
scores
- human harm evidence: 90 — labels and randomized trials
- class mechanism: 92 — 17-alpha alkylation and hepatic exposure
- safe-margin proof: 4 — no zero-risk exposure established
- marketing gap: 94 — mild and dry language hides organ risk
keep reading
- androgen category — evidence grades separated from safety
- open oxandrolone entry — withdrawn approval and burn trial
- open oxymetholone entry — body composition and liver toxicity
- Methandienone
- Stanozolol
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
